{
    "organizations": [],
    "uuid": "df46cf83d5c973534569d77f5143f7024a97452c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-health-canada-accepts-cardiomes-xy/brief-health-canada-accepts-cardiomes-xydalba-for-review-idUSFWN1R40PH",
    "ord_in_thread": 0,
    "title": "BRIEF-Health Canada Accepts Cardiome's Xydalba For Review",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 22, 2018 / 12:23 PM / Updated 9 minutes ago BRIEF-Health Canada Accepts Cardiome's Xydalba For Review Reuters Staff March 22 (Reuters) - Cardiome Pharma Corp: * HEALTH CANADA ACCEPTS CARDIOMEâ€™S XYDALBA NEW DRUG SUBMISSION AND GRANTS PRIORITY REVIEW * CARDIOME PHARMA CORP - EXPECTS TO RECEIVE AN APPROVAL DECISION FOR XYDALBA DURING Q3 OF 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-03-22T14:21:00.000+02:00",
    "crawled": "2018-03-22T14:34:09.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "canada",
        "accepts",
        "cardiome",
        "xydalba",
        "review",
        "reuters",
        "staff",
        "march",
        "reuters",
        "cardiome",
        "pharma",
        "corp",
        "health",
        "canada",
        "accepts",
        "cardiome",
        "xydalba",
        "new",
        "drug",
        "submission",
        "grant",
        "priority",
        "review",
        "cardiome",
        "pharma",
        "corp",
        "expects",
        "receive",
        "approval",
        "decision",
        "xydalba",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}